TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Stable Type 1 or Type 2 diabetes mellitus~* Visual impairment due to focal or diffuse DME in at least one eye~Exclusion Criteria:~* Active conditions in the study eye that could prevent the improvement of visual acuity on study treatment~* Active eye infection or inflammation~* History of stroke, renal failure or uncontrolled hypertension~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
- Ranibizumab Monotherapy (Type: EXPERIMENTAL): Participants received ranibizumab intravitreal injection therapy only
- Laser Monotherapy (Type: ACTIVE_COMPARATOR): Participants received Laser photocoagulation therapy only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* subjects aged from 60 days to 89 days old at the date of recruitment;~* with informed consent signed by parent(s) or guardians;~* parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions;~* subjects did not receive any vaccination within 14 days;~* axillary temperature ≤37.0℃~Exclusion Criteria:~* allergic to any ingredient of vaccine or with allergy history to any vaccine;~* acute febrile disease or infectious disease;~* serious chronic diseases;~* any other factor that makes the investigator determines the subject is unsuitable for this study;

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- sIPV+bOPV+bOPV (Type: EXPERIMENTAL): 202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
- sIPV+sIPV+bOPV (Type: ACTIVE_COMPARATOR): 197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
- sIPV+sIPV+sIPV (Type: ACTIVE_COMPARATOR): 205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Determination of the 90% Effective Dose of a Sufentanil Bolus in Analgesia During Lateral Decubitus of Mechanically Ventilated Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 48th hour of mechanical ventilation~* mechanical invasive ventilation~* 48th hour midazolam sedation~* Behavioral Pain Scale (BPS) at 3 or 4~* mechanical ventilation of 5 days duration~Exclusion Criteria:~* Pregnant or breast-feeding woman~* Impossibility of evaluation of the BPS tetraplegia, curare-link , post anoxic coma encephalic death~* Indication of deep conscious-sedation, malignant cranial trauma, toxic shock, acute respiratory distress syndrome~* Extra renal clearance OU people in hemodialysis~* Severe renal failure (creatinine clearance \<15ml/min)~* Severe hepatic failure~* State of consciousness with impossibility to use self-assessment scale~* Body mass index \>35 ou \<18~* Sufentanil midazolam paracetamol allergy or contraindication~* Guardianship or confirmed criminal Subject who give his informed consent~* Morphinic other than sufentanil (morphine, alfentanil fentanyl, remifentanil, nalbuphine, codeine, buprenorphine)~* Antalgic other than sufentanil and paracetamol ( tramadol nefopam, ketamine, dextropropoxyphene, non steroidal anti-inflammatory drug )~* MAO inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sufentanil (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects have participated in primary study HBV-280~* Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood-sampling visit of each year

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- 2-Dose Engerix (Type: EXPERIMENTAL): subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
- 3-Dose Engerix (Type: ACTIVE_COMPARATOR): subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Omega 3 as an Immunomodulator Adjunct to Periodontal Debridement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 years.~* Patients American Society of Anesthesiologists (ASA) I or ASA II compatible with local anesthesia procedures.~* Present at least 10 natural teeth, excluding semi-erupted third molars.~* Present at least 6 sites with a probing depth (PD) ≥ 5mm and clinical attachment loss (CAL) ≥ 4mm~Exclusion Criteria:~* Patients with hemostasis disorders.~* Patients who use any medication associated with gingival disorders such as: Anticonvulsants (Phenytoin), Calcium channel blockers (Nifedipine), Immunosuppressive drugs (Cyclosporins).~* Patients with systemic diseases that affect the immunoinflammatory response.~* Patients under treatment with antacids on a regular basis due to chronic gastritis and / or self-medication with antacids.~* Patients under treatment with drugs such as: warfarin, digoxin and acetylsalicylic acid.~* Previous history of allergy to local anesthetics.~* Patients presenting orthodontic appliances.~* Patients who have received antibiotic treatment in the last 3 months.~* Patients who have received periodontal treatment.~* Pregnancy.~* Carriers of valvular prostheses or failures in heart valves, with endocarditis risk.~* Patients who are physically and intellectually incapacitated to participate, according to chilean law number 20,584, title II, paragraph 8, article 28.~* Heavy smoking patients, which is smoking more than 10 cigarettes per day.~* Patients allergic to Omega 3 or seafood or its derivatives: fish, shellfish, algae, etc.~* Patients with lactose intolerance.

- Gender: ALL
- Minimum Age: 39 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Periodontal treatment, lactose tab (Type: PLACEBO_COMPARATOR): Periodontal treatment (scaling and root planning) and two tablets containing lactose once a day for 90 days immediately after the scaling and root planning.
- Periodontal treatment, Omega 3 (Type: EXPERIMENTAL): Periodontal treatment (scaling and root planning) and two tablets containing 1g of Omega 3 once a day for 90 days immediately after the scaling and root planning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of Pain Reduction by Peri-arthroscopic PRP Application in Knee Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
inclusion Criteria:~* degenerative knee pain~* age: \> 18 years~* informed consent~* none to moderate comorbidity~* arthroscopy under general anaesthesia indicated~exclusion Criteria:~* trauma of the knee within the last 6 weeks before surgery~* circumscribed cartilage lesion with possibility of repair microfracture or autologous chondrocyte transplantation - procedures~* contraindications against PRP. application~* malignancies~* severe comorbidities~* age \<18 years~* physically or mentally not able to provide informed consent~* severe knee instability~* corticosteroid injections within the last 6 weeks before surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRP (Type: EXPERIMENTAL): one intraoperative application of PRP in the interventional group
- Control (Type: NO_INTERVENTION): No application of any substance during knee arthroscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ADHD~* Diagnosis of opposition defiant disorder or conduct disorder~* Score that exceeds the study threshhold on the standardized scale of aggressive behavior~Exclusion Criteria:~* Current psychosis~* Current major depression~* Current pervasive developmental disorder~* Current obsessive compulsive disorder~* Any other anxiety disorder as primary diagnosis~* Mental retardation

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Prerandomization Inclusion Criteria:~* Provide written informed consent before initiation of any study related procedures.~* Be at least 18 years of age~* Be scheduled for Coronary Artery Bypass Grafting (CABG), Off Pump Coronary Artery Bypass (OPCAB), Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) surgery, and/or valve replacement/repair surgery~Prerandomization Exclusion Criteria:~* Women of child-bearing potential (unless they have a negative pregnancy test)~* Recent cerebrovascular accident (within 3 months before randomization)~* Known intolerance to calcium channel blockers~* Known or suspected hypersensitivity to nitroglycerin~* Allergy to soybean oil or egg lecithin (components of the lipid vehicle)~* Pre-existing permanent ventricular pacing~* Any other disease or condition, which, in the judgment of the investigator would place a patient at undue risk by being enrolled in the trial~* Participation in another therapeutic drug or therapeutic device trial within 30 days of starting study~Postrandomization Inclusion Criteria:~* Determined to be hypertensive perioperatively as determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clevidipine (Type: EXPERIMENTAL): Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
- nitroglycerin (Type: ACTIVE_COMPARATOR): Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Procalcitonin Antibiotic Consensus Trial (ProACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old~* A primary clinical diagnosis in the ED of acute LRTI (\< 28 days duration)~* Clinician willing to consider procalcitonin in antibiotic decision-making~Exclusion Criteria:~* Systemic antibiotics before ED presentation (All prophylactic antibiotic regimens, OR received \>1 dose within 72 hours prior to ED presentation)~* Current vasopressor use~* Mechanical ventilation (via endotracheal tube)~* Known severe immunosuppression~* Accompanying non-respiratory infections~* Known lung abscess or empyema~* Chronic dialysis~* Metastatic cancer~* Surgery in the past 7 days (excluding minor surgery such as skin biopsy)~* Incarcerated or homeless~* Enrolled in ProACT in the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Procalcitonin (PCT) group (Type: EXPERIMENTAL): Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
- Usual Care group (Type: ACTIVE_COMPARATOR): Telephone Visit at Day 15 and Day 30

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CRVO must have occurred within the past 6 months and be associated with macular edema determined by OCT.~* Vision in the study eye corresponding to between approximately 20/50 to 20/400 and better than or equal to approximately 20/200 in the fellow eye.~Exclusion Criteria:~* Presence of signs of old branch retinal vein occlusion (BRVO) or CRVO in the study eye or any other retinal vascular disease including diabetic retinopathy.~* Vitreous hemorrhage except breakthrough hemorrhage from intraretinal hemorrhage.~* Prior pan retinal photocoagulation (PRP) or sector scatter photocoagulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All participants living in the community will be offered treatment~Exclusion Criteria:~* Patients with a contradindication to study medication~* Patients unable to provide consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intervention Arm (Type: OTHER): This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight \<15kg) Permethrin Cream and Malathion shampoo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Not seeking treatment for drugs of abuse~* Diagnostic and Statistical Manual of Mental Disorders-IV diagnosis of cocaine dependence (not applicable for individuals enrolling as healthy controls)~* Positive urine drug screen test for cocaine (not applicable for individuals enrolling as healthy controls)~* Females must use adequate forms of contraception throughout the study~* Stable residence for the 30 days prior to enrollment~* No history of N-acetylcysteine within the 7 days prior to enrollment~* Nicotine smokers staying at the inpatient unit must use the nicotine patch during inpatient stay~Exclusion Criteria:~* Dependence on any psychoactive substance other than alcohol, nicotine, or marijuana; control subjects cannot be dependent on cocaine~* Need for medication detoxification for alcohol~* History of psychiatric disorders, including depression, bipolar disorder, post traumatic stress disorder, dementia, and organic brain disorder~* Suicidal or homicidal behavior within the 30 days prior to enrollment~* History of psychotic symptoms, including those observed during cocaine use~* History of serious medical illness, including cardiovascular disease, angina, myocardial infarction, liver disease, and kidney disease~* History of neurologic, metabolic, neoplastic, nutritional, inflammatory, or endocrine disorders~* Court requirement to receive treatment~* Expecting elective surgery within the 5 weeks prior to enrollment~* Known hypersensitivity to N-acetylcysteine~* Use of antidepressants (such as selective serotonin reuptake inhibitors or tricyclics), dopamine agonists, or psychotropic medications (such as anticonvulsants, antipsychotics, anxiolytics, or psychostimulants) within the 14 days prior to enrollment~* Pregnant or breastfeeding~* History of asthma~* History of seizures~* Participation in treatment for cocaine abuse within the 30 days prior to enrollment~* Lactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
- 1 (Type: EXPERIMENTAL): N-Acetylcysteine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with an autoimmune disease~* Clinically stable disease for at least 30 days before enrollment~* Not likely to undergo hematopoietic stem cell transplantation during the study period~* Receiving at least one parenteral or oral biologic agent, such as a Tumor Necrosis factor (TNF) alpha inhibitor, or a parenteral or oral non-biologic therapy, at a stable dose for at least 3 months, with no planned or anticipated changes~* History of varicella, antibodies to VZV, or residence for at least 30 years in a country with endemic VZV infection, or if participant is less than 30 years old, attended primary or secondary school in a country with endemic VZV infection~Exclusion Criteria:~* Prior history of Herpes Zoster (shingles) within 1 year before enrollment~* Prior varicella or zoster vaccine~* Active central nervous system lupus erythematosus requiring therapeutic intervention within 90 days of enrollment~* Prior or planned therapy containing rituximab or other anti-Cluster of Differentiation (CD) 20 monoclonal antibodies from 3 months before enrollment through 28 days postdose 4~* Systemic corticosteroid therapy, prednisone, or equivalent over 40 mg daily at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- V212 (Type: EXPERIMENTAL): Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete